Equities Analysts Set Expectations for TARA FY2025 Earnings

Protara Therapeutics, Inc. (NASDAQ:TARA) – Equities research analysts at Cantor Fitzgerald decreased their FY2025 earnings estimates for Protara Therapeutics in a research note issued on Thursday, March 20th. Cantor Fitzgerald analyst L. Watsek now forecasts that the company will earn ($1.71) per share for the year, down from their previous forecast of ($1.62). Cantor Fitzgerald currently has a “Overweight” rating on the stock. The consensus estimate for Protara Therapeutics’ current full-year earnings is ($3.32) per share.

Protara Therapeutics (NASDAQ:TARA) last released its quarterly earnings results on Wednesday, March 12th. The company reported ($0.48) earnings per share for the quarter, beating the consensus estimate of ($0.57) by $0.09.

Other research analysts have also recently issued research reports about the company. Guggenheim reiterated a “buy” rating and set a $20.00 price objective on shares of Protara Therapeutics in a research report on Friday, December 6th. Lifesci Capital started coverage on shares of Protara Therapeutics in a research note on Tuesday, March 11th. They issued an “outperform” rating and a $22.00 price target on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $23.00 price objective on shares of Protara Therapeutics in a research note on Thursday, March 6th. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, Protara Therapeutics presently has an average rating of “Buy” and a consensus price target of $22.50.

Protara Therapeutics Trading Up 2.2 %

Shares of NASDAQ TARA opened at $4.70 on Monday. The firm has a market cap of $172.80 million, a P/E ratio of -1.67 and a beta of 1.69. The business’s 50 day moving average is $4.28 and its 200-day moving average is $3.60. Protara Therapeutics has a 1-year low of $1.60 and a 1-year high of $10.48.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of TARA. HBK Investments L P bought a new stake in Protara Therapeutics during the fourth quarter worth about $106,000. Squarepoint Ops LLC acquired a new position in shares of Protara Therapeutics in the 4th quarter valued at approximately $110,000. Dimensional Fund Advisors LP bought a new stake in shares of Protara Therapeutics during the 4th quarter worth approximately $111,000. Bailard Inc. acquired a new stake in shares of Protara Therapeutics during the 4th quarter worth approximately $157,000. Finally, XTX Topco Ltd bought a new position in Protara Therapeutics in the third quarter valued at approximately $60,000. Institutional investors own 38.13% of the company’s stock.

Protara Therapeutics Company Profile

Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.